Allis.health – a digital health analyst in your pocket

After the breakneck pace of development in the digital health category during the pandemic, 2023 looks like it could be a pivotal year, with financing levels falling and the first major casualties among pioneering start-ups as commercial realities take hold.

So, where is the direction of travel from here? A new digital health analysis platform called Allis.health – originated by analyst and strategy consulting company Research2Guidance (R2G) and developed by pharmaphorum parent Healthware Group – promises to provide signposts for those navigating the sector.

The platform continuously monitors the digital health environment and provides analysts’ perspective, keeping users up-to-date more efficiently than a snapshot market analysis report, for example, and recognising that markets and competitors are developing at a breakneck pace.

Allis.health also organises data into specific channels by market segment, recognising that the digital health market is large and diverse and different categories have varying dynamics.

It features a News Watch section to curate pertinent news within each market segment, and a Competitor Watch track to monitor the activities of hundreds of organisations and their activities, including partnerships, client wins, product developments, funding rounds, regulatory approvals, and clinical evidence demonstrations.

Alongside that, a Market Watch section provides analysis of market segment trends with five-minute analyst notes, video interviews, and deep-dive presentations.

“We created Allis.health with the aim of offering digital health managers, investors, researchers, or even consultants a market and competitor monitoring tool for the global digital health market to support their tactical and strategic decisions,” said Ralf Jahns, managing director of R2G.

“The platform is designed to provide ongoing insights into market trends, ensuring accessibility and relevance beyond individual projects,” he added.

Allis.health launches with diabetes, oncology, and digital therapeutics (DTx) channels, with plans to expand into mental health, artificial intelligence-powered drug discovery, cardiovascular, femtech, clinical trials, and more by mid-2024.

“Recognising the challenge of staying on top of such a rapidly growing and changing industry, Healthware is proud to have partnered with R2G to develop such a robust and meaningful market intelligence platform to cover the digital health industry,” said Roberto Ascione, chief executive and founder of Healthware Group.

Photo by Scott Graham on Unsplash.